Lipiodol
Payments companies reported to CMS as associated with Lipiodol. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Lipiodol, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Lipiodol
These are the largest totals companies reported as associated with Lipiodol. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Michael Soulen | Philadelphia, PA | Vascular & Interventional Radiology | $51,678.84 |
| Maxim Itkin | Wilmington, DE | Pediatric Radiology | $30,236.88 |
| Julius Chapiro | New Haven, CT | Diagnostic Radiology | $28,891.48 |
| Richard Finn | Santa Monica, CA | Hematology & Oncology | $25,303.83 |
| Rony Avritscher | Houston, TX | Vascular & Interventional Radiology | $21,842.61 |
| David Madoff | New Haven, CT | Diagnostic Radiology | $19,788.56 |
| John Walker | San Antonio, TX | Vascular & Interventional Radiology | $15,000.00 |
| Jorge Lopera | San Antonio, TX | Vascular & Interventional Radiology | $15,000.00 |
| Marcelo Guimaraes | Charleston, SC | Vascular & Interventional Radiology | $9,516.65 |
| Mishal Mendiratta Lala | Ann Arbor, MI | Diagnostic Radiology | $9,000.00 |
Prescribed Lipiodol?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.